SCHEMBL24137538

SCHEMBL24137538

Clc1ccc(NCc2cncc(-c3ccc4[nH]ncc4c3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.50
▸ FGFR1 P11362 1/20 0.49
▸ CLK1 P49759 6/20 0.47
▸ CLK2 P49760 6/20 0.47
▸ DYRK1A Q13627 6/20 0.47
▸ CLK4 Q9HAZ1 6/20 0.47
▸ DYRK1B Q9Y463 5/20 0.47
▸ CLK3 P49761 3/20 0.47
▸ CDK2 P24941 3/20 0.47
▸ NOS1 P29475 1/20 0.47
▸ ROCK2 O75116 5/20 0.47
▸ GSK3B P49841 3/20 0.47
▸ AURKB Q96GD4 2/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ CCNC P24863 1/20 0.46
▸ CDK8 P49336 1/20 0.46
▸ TRPM5 Q9NZQ8 1/20 0.46
▸ ROCK1 Q13464 3/20 0.46
▸ PRKD3 O94806 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137567 0.88 DYRK1A (0.56) FDPSFGFR1CLK1CLK2DYRK1A
SCHEMBL24137792 0.81 JAK2 (0.50) CLK2DYRK1ACLK4CLK3CDK2
SCHEMBL22191810 0.80 THRB (0.53) DYRK1AAKT1
SCHEMBL13122152 0.80 TRPM5 (0.60) CLK2DYRK1ACLK4NOS1ROCK2
SCHEMBL24137563 0.79 CCNC (0.61) FDPSFGFR1CLK1CLK2DYRK1A
SCHEMBL19882573 0.77 DYRK1A (0.57) FDPSFGFR1CLK1CLK2DYRK1A
SCHEMBL16740690 0.76 NOS1 (0.72) FGFR1CLK1CLK2DYRK1ACLK4
SCHEMBL24137909 0.75 CCNC (0.54) FGFR1CLK1CLK2DYRK1ACLK4
SCHEMBL25933932 0.75 DYRK1A (0.50) FDPSCLK1CLK2DYRK1ACLK4
SCHEMBL25933934 0.73 CCNC (0.44) FDPSCLK1CLK2DYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 FDPS 4594/4885FGFR1 600/4885CLK1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback